NewAmsterdam Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 62 to 74.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they begin their largest price moves. See if NewAmsterdam Pharma can continue to show renewed price strength and hit that benchmark.
NewAmsterdam Pharma is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could kick off a new climb.
NewAmsterdam Pharma posted 0% EPS growth in its most recent report, while sales growth came in at 1,385%. Look for the next report on or around May 7.
The company holds the No. 115 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
